Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs. Head & neck Benjamin, W. J., Yalamanchi, P., Taylor, J. M., Lenze, N., Worden, F. P., Chinn, S. B., Chen, M. M. 2023

Abstract

The impact of monoclonal antibody therapy (mAB) for advanced head and neck cancer on end-of-life health care utilization and costs has yet to be adequately studied.Retrospective cohort study of patients aged 65 and over with a diagnosis of head and neck cancer between 2007 and 2017 within the SEER-Medicare registry assessing the impact of mAB therapy (i.e., cetuximab, nivolumab, or pembrolizumab) on end-of-life health care utilization (ED visits, inpatient admissions, ICU admissions, and hospice claims) and costs.Of 12?544 patients with HNC, 270 (2.2%) utilized mAB therapy at the end-of-life period. On multivariable analyses adjusting for demographic and clinicopathologic characteristics, there was a significant association between mAB therapy and emergency department visits (OR: 1.38, 95% CI: 1.1-1.8, p?=?0.01) and healthcare costs (ß: $9760, 95% CI: 5062-14?458, p?

View details for DOI 10.1002/hed.27359

View details for PubMedID 36976786